Consortium receives NWO subsidy for research on more effective treatment of depression

Depression is the leading cause of disability. Patients receive treatment on a trial-and-error basis because it is unknown which treatment will benefit a patient. The BOOST Depression consortium will use artificial intelligence to develop biomarkers that can predict treatment outcome and guide the selection of the best treatment for each patient. This is expected to double the treatment success rate, shorten treatment trajectories, and reduce health care costs. The Dutch research organization NWO granted a subsidy of 4,6 million euro’s to the project.